Department of Organ Transplantation, Unidad Médica de Alta Especialidad (UMAE), Hospital Especialidades 14 "Adolfo Ruiz Cortines", Instituto Mexicano del Seguro Social (IMSS), Veracruz.
Department of General Surgery, UMAE, Hospital Especialidades 14 "Adolfo Ruiz Cortines",IMSS, Veracruz.
Cir Cir. 2022;90(5):602-609. doi: 10.24875/CIRU.22000063.
The Mexican Hepato-Pancreato-Biliary Association (AMHPB) conducted a survey, aiming to gather experience and opinions of HPB surgeons about HPB surgery in the 2020 COVID-19 pandemic year.
An online survey was conducted (33 items: demographics, patient referral, COVID-19 screening and limitations, hospital occupancy and surgical practice) to AMHPB members and attendees of the previous meetings of the Society through a self-administered questionnaire. Answers were excluded if respondents were not from Latin America.
88 participants answered (47.5 ± 10 years, 94% male and 65.9% Mexicans). About 8% worked in COVID-19 converted hospitals. About 1.1% did not perform pre-operative COVID-19 testing. Polymerase chain reaction (33%) was the most common COVID-19 pre-operative test. The number of patient referrals decreased 62.5%. About 29.5% had one patient who died from COVID-19 during preoperative surgical evaluation. About 64.7% answered that surgical case volume decreased. About 17% and 23% respondents considered that surgical morbidity and mortality increased, respectively. Hospital resources and COVID-19 infection were responsible for change in surgical outcomes. Lack of ICU beds (54%) was the most common cause of surgical cancellation.
COVID-19 had a strong negative impact on HPB surgery in Mexico and Latin America in terms of patient reference, case volume and surgical outcomes.
墨西哥肝胆胰胆协会（AMHPB）进行了一项调查，旨在收集肝胆胰胆外科医生在 2020 年 COVID-19 大流行期间进行肝胆胰胆手术的经验和意见。
通过自我管理问卷，向 AMHPB 成员和前协会会议的与会者进行了一项在线调查（33 项：人口统计学、患者转诊、COVID-19 筛查和限制、医院入住率和手术实践）。如果受访者不是来自拉丁美洲，则排除答案。
88 名参与者回答（47.5±10 岁，94%男性，65.9%墨西哥人）。约 8%的人在 COVID-19 转换医院工作。约 1.1%的人没有进行术前 COVID-19 检测。聚合酶链反应（33%）是最常见的 COVID-19 术前检测。患者转诊数量减少了 62.5%。约 29.5%的人在术前手术评估期间有一名患者死于 COVID-19。约 64.7%的人回答手术量减少。约 17%和 23%的受访者分别认为手术发病率和死亡率增加。外科手术结果的变化是由医院资源和 COVID-19 感染引起的。缺乏 ICU 床位（54%）是手术取消的最常见原因。
COVID-19 对墨西哥和拉丁美洲的肝胆胰胆手术产生了强烈的负面影响，表现在患者参考、病例数量和手术结果方面。
